Docent och universitetslektor
Forskningsområden
- Sociologi (exklusive socialt arbete, socialpsykologi och socialantropologi)
- Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi
Forskning
Jag är intresserad av hur marknadskrafter, statlig reglering och medicinsk vetenskap påverkar läkemedelsutveckling och läkemedelsanvändning i samhället. Ett tema i min forskning är regleringen av läkemedelsindustrins marknadsföring och transparens. I ett pågående projekt finansierat av Vetenskapsrådet analyserar vi transparens vad gäller finansiella relationer mellan läkemedelsbolag och andra aktörer som t.ex. läkare och patientorganisationer.
Ett annat tema i min forskning är hur myndigheter utvärderar läkemedel samt hur ekonomiska, politiska och organisatoriska förutsättningar kan påverka myndighetsbeslut. Jag har bland annat skrivit om hur läkemedelsmyndigheter i USA och Europa utvärderat influensaläkemedel.
Ytterligare ett spår i min forskning är mer klassiska kunskapssociologiska teman såsom hur vetenskapliga ”tankestilar” samt finansiella, professionella och vetenskapliga intressen påverkar forskningens innehåll och utveckling. Jag har bland annat skrivit om hur finansiella och vetenskapliga intressen först sammanföll för att sedan kollidera under utvecklingen av läkemedelsbolaget Astras antidepressiva läkemedel Zelmid. Jag har också beskrivit hur bio-psykiatriska teoriers utveckling sedan 1960-talet varit starkt betingat av vilka psykiatriska läkemedel som varit tillgängliga att undersöka i experimentell forskning. I ett pågående projekt finansierat av The Wallenberg AI, Autonomous Systems and Software Program – Humanities and Society (WASP-HS) studerar vi konsekvenserna av att introducera artificiell intelligens i biomedicin.
Slutligen är jag intresserad av användingen av sociala kategorier, främst ras- och etnicitetskategorier, inom medicinisk forskning och särskilt läkemedelsforskning. I ett pågående projekt finansierat av Vetenskapsrådet analyserar vi därför användingen av ras- och etnicitetskategorier i medicinsk forskning, policy och praktik.
Publikationer
Visar av publikationer. Sorterade efter år och sen titel.
Broken beyond repair: self regulation of industry payments to clinicians and hospitals
Piotr Ozieranski, Shai Mulinari
(2024) BMJ: British Medical Journal, 386
Artikel i tidskriftContinued cancer drug approvals in Japan and Europe after market withdrawal in the United States : A comparative study of accelerated approvals
Hayase Hakariya, Frank Moriarty, Akihiko Ozaki, Shai Mulinari, Hiroaki Saito, et al.
(2024) Clinical and Translational Science, 17 p.13879-13879
Artikel i tidskriftPatterns of company misconduct, recidivism, and complaint resolution delays : A temporal analysis of UK pharmaceutical industry self-regulation within the European context
Shai Mulinari, Dylan Pashley, Piotr Ozieranski
(2024) Regulation and Governance
Artikel i tidskriftEvaluating time to withdrawal of anti-cancer drug indications that received FDA's accelerated approval
Hayase Hakariya, Akihiko Ozaki, Shai Mulinari, Frank Moriarty, Tetsuya Tanimoto
(2024) QJM - Monthly Journal of the Association of Physicians
Artikel i tidskriftPayments to healthcare organisations reported by the medical device industry in Europe from 2017 to 2019 : An observational study
James Larkin, Shai Mulinari, Piotr Ozieranski, Kevin Lynch, Tom Fahey, et al.
(2024) Health Policy and Technology, 13
Artikel i tidskriftDelays in dealing with complaints against drug companies are growing, BMJ finds
Hristio Boytchev, Shai Mulinari, Piotr Ozieranski
(2024) BMJ (Clinical research ed.), 384 p.365-365
Artikel i tidskriftAuthors’ reply to Fell
Shai Mulinari, Piotr Ozieranski
(2023) British Medical Journal, 383
Artikel i tidskriftPharmaceutical industry payments to NHS trusts in England : A four-year analysis of the Disclosure UK database
Piotr Ozieranski, Eszter Saghy, Shai Mulinari
(2023) PLoS ONE, 18
Artikel i tidskriftUnethical pharmaceutical marketing: a common problem requiring collective responsibility
Shai Mulinari, Piotr Ozieranski
(2023) BMJ (Clinical research ed.), 382
Artikel i tidskriftRace in clinical trials in Sweden: how regulatory and medical standards in clinical research trump the post-racial discourse
Shai Mulinari, Anna Bredström
(2023) Sociology of Health & Illness
Artikel i tidskriftInternational comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency
Piotr Ozieranski, Hiroaki Saito, Emily Rickard, Shai Mulinari, Akihiko Ozaki
(2023) Globalization and Health, 19 p.1-42
Artikel i tidskriftConceptual unclarity about COVID-19 ethnic disparities in Sweden: Implications for public health policy
Anna Bredström, Shai Mulinari
(2023) Health, 27 p.186-200
Artikel i tidskriftShort-circuiting biology: Digital phenotypes, digital biomarkers, and shifting gazes in psychiatry
Shai Mulinari
(2023) Big Data and Society
Artikel i tidskrift“Black race”, “Schwarze Hautfarbe”, “Origine africaine”, or “Etnia nera”? The absent presence of race in European pharmaceutical regulation
Shai Mulinari, Anna Bredström
(2022) BioSocieties
Artikel i tidskriftDe unga gör helt rätt när de stämmer staten
Christina Moberg, Hervé Corvellec, Anders Lindroth, Manuela Isacson, Linn Nilsson, et al.
(2022) Aftonbladet
TidningsartikelThe making of a Swedish strategy : How organizational culture shaped the Public Health Agency's pandemic response
Tobias Olofsson, Shai Mulinari, Maria Hedlund, Åsa Knaggård, Andreas Vilhelmsson
(2022) SSM Qualitative Research in Health, 2
Artikel i tidskriftContent and strength of conflict of interest policies at Scandinavian Medical Schools: a cross sectional study
Alice Fabbri, Shai Mulinari, Martin Johansson, Weda Ghaur, Abdullah Muhammad Khalil, et al.
(2022) BMC Medical Education, 22
Artikel i tidskriftAdvancing international comparison of pharmaceutical industry funding of patient advocacy: Focus on Denmark
Shai Mulinari, Dylan Pashley, Piotr Ozieranski
(2022) Health Policy, 126 p.1256-1262
Artikel i tidskriftDisclosure of Pharmaceutical Industry Funding of Patient Organisations in Nordic Countries: Can Industry Self-Regulation Deliver on its Transparency Promise?
Dylan Pashley, Piotr Ozieranski, Shai Mulinari
(2022) International Journal of Health Services, 52 p.347-362
Artikel i tidskriftTip of the iceberg? Country- and company-level analysis of drug company payments for research and development in Europe
Piotr Ozieranski, Luc Martinon, Pierre-Alain Jachiet, Shai Mulinari
(2022) International Journal of Health Policy and Management, 11 p.2842-2859
Artikel i tidskriftCapitalizing on transparency: commercial surveillance and pharmaceutical marketing after the Physician Sunshine Act
Shai Mulinari, Piotr Ozieranski
(2022) Big Data and Society, 9
Artikel i tidskriftA “patient-industry complex”? Investigating the financial dependency of UK patient organisations on drug company funding
Piotr Ozieranski, Pitter Janos, Emily Rickard, Shai Mulinari, Marcell Csanadi
(2022) Sociology of Health & Illness, 44 p.188-210
Artikel i tidskriftAccessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: A European policy review
Piotr Ozieranski, Luc Martinon, Pierre-Alain Jachiet, Shai Mulinari
(2021) BMJ Open, 11
Artikel i tidskriftDrug company payments to General Practices in England: cross-sectional and social network analysis
Eszter Saghy, Shai Mulinari, Piotr Ozieranski
(2021) PLoS ONE, 16
Artikel i tidskriftPharmaceutical industry self-regulation and non-transparency : country and company level analysis of payments to healthcare professionals in seven European countries
Shai Mulinari, Luc Martinon, Pierre-Alain Jachiet, Piotr Ozieranski
(2021) Health Policy, 125 p.915-922
Artikel i tidskriftIs there evidence for the racialization of pharmaceutical regulation? : Systematic comparison of new drugs approved over five years in the USA and the EU
Shai Mulinari, Andreas Vilhelmsson, Piotr Ozieranski, Anna Bredström
(2021) Social Science and Medicine, 280
Artikel i tidskriftData Transparency and Pharmaceutical Regulation in Europe : Road to Damascus, or Room without a View?
Courtney Davis, Shai Mulinari, Tom Jefferson
(2021) Transparency, Power, and Influence in the Pharmaceutical Industry : Policy Gain or Confidence Game? , p.63-94
Del av eller Kapitel i bokSociologisk forskning om covid-19-pandemin : En introduktion
Shai Mulinari, Linda Soneryd, Susanna Öhman
(2021) Sociologisk Forskning, 58 p.5-15
Artikel i tidskriftFailure of responsive regulation? : Pharmaceutical marketing, corporate impression management and off-label promotion of enzalutamide in Europe
Shai Mulinari, Courtney Davis, Piotr Ozieranski
(2021) Journal of White Collar and Corporate Crime, 2 p.69-80
Artikel i tidskriftSweden
Tobias Olofsson, Andreas Vilhelmsson, Maria Hedlund, Åsa Knaggård, Shai Mulinari
(2021) Comparative Covid Response : Crisis, Knowledge, Politics
RapportPharmaceutical lobbying and pandemic stockpiling : A feeling of déjà vu in the Nordic countries and why the sociological perspective is crucial to understand COVID-19
Andreas Vilhelmsson, Shai Mulinari
(2020) Acta Sociologica, 63 p.439-442
Artikel i tidskriftUnder-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012-2016)
Piotr Ozieranski, Marcell Csanadi, Emily Rickard, Shai Mulinari
(2020) BMJ Open, 10 p.1-11
Artikel i tidskriftFive years of pharmaceutical industry funding of patient organisations in Sweden: cross-sectional study of companies, patient organisations and drugs
Shai Mulinari, Andreas Joakim Vilhelmsson, Emily Rickard, Piotr Ozieranski
(2020) PLoS ONE
Artikel i tidskriftSociologiska perspektiv på coronakrisen : Fyra sociologer om samhällets reaktion på covid-19
Erna Danielsson, Fredrik Liljeros, Shai Mulinari, Linda Soneryd
(2020) Sociologisk Forskning, 57 p.67-76
Artikel i tidskriftRevisiting the pharmaceuticalisation of pandemic influenza using Lukes’ framework of power
Shai Mulinari, Andreas Vilhelmsson
(2020) Sociology of Health & Illness, 42 p.327-341
Artikel i tidskriftThe will of Congress? Permissive regulation and the strategic use of labeling for the anti-influenza drug Relenza
Shai Mulinari, Courtney Davis
(2020) Social Studies of Science, 50 p.145-169
Artikel i tidskriftRas och genetiska skillnader : Introduktion till avsnittets texter
Shai Mulinari
(2020) Fronesis , p.20-23
Artikel i tidskriftBengt Olle Bengtsson intervjuad av Shai Mulinari : Om genetisk likhet och skillnad
Bengt Olle Bengtsson, Shai Mulinari
(2020) Fronesis , p.24-38
Artikel i tidskriftRas i genetikens tidevarv
Shabane Barot, Anna Bredström, Shai Mulinari, Mani Shutzberg
(2020) Fronesis , p.8-17
Artikel i tidskriftSvenska gener? : Om stratifierad precisionsmedicin och genetikens etniska gränsdragningar
Anna Bredström, Shai Mulinari
(2020) Fronesis , p.65-81
Artikel i tidskriftEvaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK
Emily Richard, Piotr Ozieranski, Shai Mulinari
(2019) Health Policy, 123 p.1244-1250
Artikel i tidskriftThe whistleblowing drama behind Astellas’s suspension from the ABPI
Deborah Cohen, Shai Mulinari, Piotr Ozieranski
(2019) BMJ: British Medical Journal, 366
Artikel i tidskriftAnalysis of Pharmaceutical Industry Payments to UK Health Care Organizations in 2015
Piotr Ozieranski, Marcell Csanadi, Emily Rickard, Jordan Tchilingirian, Shai Mulinari
(2019) JAMA Network Open, 2 p.196253-196253
Artikel i tidskriftExposing drug industry funding of UK patient organisations
Piotr Ozieranski, Emily Richard, Shai Mulinari
(2019) BMJ: British Medical Journal, 365
Artikel i tidskriftExplaining biological depression theories
Shai Mulinari
(2018) Philosophy, Psychiatry, and Psychology, 4 p.309-310
Artikel i tidskriftLet the drugs lead the way! : On the unfolding of a research programme in psychiatry
Shai Mulinari
(2018) Philosophy, Psychiatry, and Psychology, 4 p.289-302
Artikel i tidskriftRegulatory scientists' work has important ramifications for public health and should be open to public scrutiny
Shai Mulinari, Courtney Davis
(2018) Health Research Policy and Systems, 2018 p.98-98
Artikel i tidskriftOveruse of methylphenidate : an analysis of Swedish pharmacy dispensing data
Pernilla J Bjerkeli, Raquel Perez Vicente, Shai Mulinari, Kristina Johnell, Juan Merlo
(2018) Clinical Epidemiology, 10 p.1657-1665
Artikel i tidskriftDisclosure of payments by pharmaceutical companies to healthcare professionals in the United Kingdom: analysis of the Association of the British Pharmaceutical Industry’s Disclosure UK database, 2015 and 2016 cohorts
Shai Mulinari, Piotr Ozieranski
(2018) BMJ Open, 8
Artikel i tidskriftSunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries
Alice Fabbri, Ancel.la Santos, Signe Mezinska, Shai Mulinari, Barbara Mintzes
(2018) International Journal of Health Policy and Management, 7 p.504-509
Artikel i tidskriftChronic Obstructive Pulmonary Disease in Sweden: an intersectional multilevel analysis of individual heterogeneity and discriminatory accuracy
Sten Axelsson Fisk, Shai Mulinari, Maria Wemrell, George Leckie, Raquel Perez Vicente, et al.
(2018) SSM - Population Health, 4 p.334-346
Artikel i tidskriftCategorical and anti-categorical approaches to US racial/ethnic groupings: revisiting the National 2009 H1N1 Flu Survey (NHFS)
Shai Mulinari, Maria Wemrell, Björn Rönnerstrand, SV Subramanian, Juan Merlo
(2018) Critical Public Health, 28 p.177-189
Artikel i tidskriftPharmaceutical lobbying and pandemic stockpiling of Tamiflu: a qualitative study of arguments and tactics
Andreas Vilhelmsson, Shai Mulinari
(2018) Journal of Public Health, 40 p.646-651
Artikel i tidskriftSociodemographic patterns in pharmacy dispensing of medications for erectile dysfunction in Sweden
Pernilla J Bjerkeli, Shai Mulinari, Sofia Zettermark, Juan Merlo
(2018) European Journal of Clinical Pharmacology, 74 p.209-218
Artikel i tidskriftThe tyranny of the averages and the indiscriminate use of risk factors in public health : The case of coronary heart disease
Juan Merlo, Shai Mulinari, Maria Wemrell, S V Subramanian, Bo Hedblad
(2017) SSM - Population Health, 3 p.684-698
Artikel i tidskriftWhy European and United States drug regulators are not speaking with one voice on anti-influenza drugs: regulatory review methodologies and the importance of 'deep' product reviews
Shai Mulinari, Courtney Davis
(2017) Health Research Policy and Systems, 15
Artikel i tidskriftIntersectionality and risk of ischemic heart disease in Sweden: categorical and anti-categorical approaches
Maria Wemrell, Shai Mulinari, Juan Merlo
(2017)
Konferens - annatTwo thirds of Survey Respondents in Southern Sweden used Complementary or Alternative Medicine (CAM) in 2015
Maria Wemrell, Juan Merlo, Shai Mulinari, Anne-Christine Hornborg
(2017) Complementary Medicine Research, 24 p.302-309
Artikel i tidskriftIntersektionalitet och risk för ischemisk hjärtsjukdom i Sverige
Maria Wemrell, Shai Mulinari, Juan Merlo
(2017) BestPractice Diabetes / Hjärtkärlsjukdomar i Sverige, 2017
Artikel i tidskriftAn intersectional approach to multilevel analysis of individual heterogeneity (MAIH) and discriminatory accuracy
Maria Wemrell, Shai Mulinari, Juan Merlo
(2017) Social Science and Medicine, 178 p.217-219
Artikel i tidskriftIntersectionality and risk for ischemic heart disease in Sweden: Categorical and anti-categorical approaches
Maria Wemrell, Shai Mulinari, Juan Merlo
(2017) Social Science and Medicine, 177 p.213-222
Artikel i tidskriftUnhealthy marketing of pharmaceutical products: An international public health concern
Shai Mulinari
(2016) Journal of Public Health Policy, 37 p.149-159
Artikel i tidskriftContemporary Epidemiology : A Review of Critical Discussions Within the Discipline and A Call for Further Dialogue with Social Theory
Maria Wemrell, Juan Merlo, Shai Mulinari, Anne-Christine Hornborg
(2016) Sociology Compass, 10 p.153-171
Artikel i tidskriftRegulating Pharmaceutical Industry Marketing: Development, Enforcement and Outcome of Marketing Rules
Shai Mulinari
(2016) Sociology Compass, 10 p.74-86
Artikel i tidskriftPharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012.
Andreas Vilhelmsson, Courtney Davis, Shai Mulinari
(2016) PLoS Medicine, 13
Artikel i tidskriftTestosterone prescribing in the population-a short social epidemiological analysis in Sweden.
Pernilla Bjerkeli, Shai Mulinari, Juan Merlo
(2016) Pharmacoepidemiology and Drug Safety, 25 p.11-15
Artikel i tidskriftAppropriate assessment of ethnic differences in adolescent use of psychotropic medication: multilevel analysis of discriminatory accuracy.
Anna-Karin Ivert, Shai Mulinari, Willemijn van Leeuwen, Philippe Wagner, Juan Merlo
(2016) Ethnicity and Health, 21 p.578-595
Artikel i tidskriftAnvändning av alternativ och komplementär medicin (AKM) i Skåne: Pilotstudie 2016
Maria Wemrell, Juan Merlo, Shai Mulinari, Anne-Christine Hornborg
(2016)
RapportDoes Maternal Country of Birth Matter for Understanding Offspring’s Birthweight? A Multilevel Analysis of Individual Heterogeneity in Sweden
Shai Mulinari, Sol Pia Juarez, Philippe Wagner, Juan Merlo
(2015) PLoS ONE, 10
Artikel i tidskriftMånga allvarliga brott mot regler när läkemedel marknadsförs
Shai Mulinari
(2015) Läkartidningen, 112 p.703-703
Artikel i tidskriftComplaints, Complainants, and Rulings Regarding Drug Promotion in the United Kingdom and Sweden 2004–2012: A Quantitative and Qualitative Study of Pharmaceutical Industry Self-Regulation
Anna Zetterqvist, Juan Merlo, Shai Mulinari
(2015) PLoS Medicine, 12
Artikel i tidskriftQuestioning the discriminatory accuracy of broad migrant categories in public health: self-rated health in Sweden
Shai Mulinari, Anna Bredström, Juan Merlo
(2015) European Journal of Public Health, 25 p.911-917
Artikel i tidskriftDivergence and convergence of commercial and scientific priorities in drug development: the case of Zelmid, the first SSRI antidepressant
Shai Mulinari
(2015) Social Science and Medicine, 138 p.217-224
Artikel i tidskriftMeasures of discriminatory accuracy and categorizations in public health: a response to Allan Krasnik's editorial.
Juan Merlo, Shai Mulinari
(2015) European Journal of Public Health, 25 p.910-910
Artikel i tidskriftEtik och marknadsföring: Skäl till självkritik?
Shai Mulinari
(2015) Pharma Industry, 2 p.28-30
Artikel i tidskriftMoney, Money, Money? Politico-Moral Discourses of Stem Cell Research in a Grant Allocation Process
Shai Mulinari, Tora Holmberg, Malin Ideland
(2015) Science & Technology Studies, 28 p.53-72
Artikel i tidskriftReplik, etik och marknadsföring: Inte för sent för reformer
Shai Mulinari
(2015) Läkartidningen, 112
Artikel i tidskriftThe specificity triad: notions of disease and therapeutic specificity in biomedical reasoning
Shai Mulinari
(2014) Philosophy Ethics and Humanities in Medicine, 9
Artikel i tidskriftMisleading advertising for antidepressants in sweden: a failure of pharmaceutical industry self-regulation.
Anna Zetterqvist, Shai Mulinari
(2013) PLoS ONE, 8
Artikel i tidskriftRegulating drug information in Europe: a pyrrhic victory for pharmaceutical industry critics?
Shai Mulinari
(2013) Sociology of Health & Illness, 35 p.761-777
Artikel i tidskriftGenetics and democracy-what is the issue?
Niclas Hagen, Maria Hedlund, Susanne Lundin, Shai Mulinari, Ulf Kristoffersson
(2012) Journal of Community Genetics
Artikel i tidskriftSlapp hantering av läkemedelsindustrin skadar Läkemedelsverkets trovärdighet
Shai Mulinari
(2012) Läkartidningen, 109 p.2107-2107
Artikel i tidskriftMonoamine theories of depression: historical impact on biomedical research
Shai Mulinari
(2012) Journal of the History of the Neurosciences, 21 p.366-392
Artikel i tidskriftRegulating drug information in Europe: a pyrrhic victory for countervailing forces?
Shai Mulinari
(2012)
Konferensbidrag: abstractVarför fara med osanningar om depressioners orsaker?
Shai Mulinari
(2011) Läkartidningen, 108 p.1839-1840
Artikel i tidskriftRho-guanine nucleotide exchange factors during development: Force is nothing without control.
Shai Mulinari, Udo Häcker
(2010) Small GTPases, 1 p.28-43
Artikel i tidskriftHedgehog, but not Odd skipped, induces segmental grooves in the Drosophila epidermis.
Shai Mulinari, Udo Häcker
(2009) Development: For advances in developmental biology and stem cells, 136 p.3875-3880
Artikel i tidskriftFrom Cell Shape to Body Shape: Epithelial Morphogenesis in Drosophila melanogaster
Shai Mulinari
(2008) Lund University Faculty of Medicine Doctoral Dissertation Series, 2008:82
DoktorsavhandlingDRhoGEF2 and Diaphanous Regulate Contractile Force during Segmental Groove Morphogenesis in the Drosophila Embryo.
Shai Mulinari, Mojgan Padash, Udo Häcker
(2008) Molecular Biology of the Cell, 19 p.1883-1892
Artikel i tidskriftExpression and regulation of Spätzle-processing enzyme in Drosophila.
Shai Mulinari, Udo Häcker, Casimiro Castillejo-Lopez
(2006) FEBS Letters, 580 p.5406-5410
Artikel i tidskrift
Registrering och rapportering av läkemedelsförsök på människor
Shai Mulinari presenterar "Vi har kommit långt. Datatransparens och läkemedelsreglering i Europa” på Cochrane Swedens webinarium, 17 juni 2021. Presentationen är på engelska.
Transparens inom läkemedelsindustrin – därför är det viktigt.
Se Shai Mulinaris föreläsning, en Crafoord Vetenskapslunch inspelad på Lunds stadsbibliotek, 7 oktober 2020.